RESILIENCE helps you survive cancer with a strong heart

Full house at The Science and Innovation Week

On Thursday, November 17th we participated in the XXII Week of Science and Innovation in Madrid with our activity “Visit to a CNIC laboratory to learn about the use of technology and its innovative aspects in the RESILIENCE project”. More than 60 people of different ages, students and professionals from different sectors, attended the activity […]

RESILIENCE in Portugal

On November 2nd, RESILIENCE team traveled to Portugal to visit the two medical centers that have just joined our RESILIENCE project, Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E. (IPO) and Hospital Da Luz. Both hospitals will collaborate in the growth of our project in the Portuguese country; IPO will identify and recruit the […]

Opening of new centers

We are glad to announce that in October 13th new centers have joined the RESILIENCE project, welcome to our team to Hospital Clínico Universitario de Valladolid! This is great news as during the summer 2022 three new sites have also been opened: • Hospital Universitario de Salamanca, July 22nd. • University of Dusseldorf (UDUS), August […]

Anthracycline-induced cardiotoxicity: what cardiologist can do about it

We were at the European Society of Cardiology Barcelona 22 congress at the end of August, where Borja Ibáñez, Director of the Clinical Research Department at Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) and Coordinator of the RESILIENCE project discussed the role of cardiologist on the anthracycline-induced cardiotoxicity along with Teresa López Fernández, Head […]

RESILIENCE clinical trial

Our RESILIENCE team has prepared this video in which we explain how the therapy is randomized for the RESILIENCE clinical trial. For this procedure, we will use the electronic case report form (e-CRF), a software that will assign one of the corresponding therapies randomly. The research team will access to the e-CRF via the website […]

RESILIENCE TALKS – Leaders of the Future

Interview with Alberto López-García – Fundación Jiménez Díaz University Hospital (IIS-FJD) Alberto is a young researcher leading an important part of the project. Alberto represents the young community of the project. One of the goals of RESILIENCE is to identify the European leaders of the future. Could you tell us a bit about yourself? I […]

CNIC coordina RESILIENCE, un proyecto diseñado para reducir la insuficiencia cardíaca en pacientes con cancer

La Comisión Europea, a través del programa H2020 “Salud, Cambio Demográfico y Bienestar”, ha designado al Centro Nacional de Investigaciones Cardiovasculares (CNIC) como coordinador de RESILIENCE (REmote iSchemic condItioning in Lymphoma PatIents REceiving ANthraCyclinEs), un ambicioso proyecto especialmente diseñado para desarrollar una nueva intervención médica destinada a reducir la prevalencia de la insuficiencia cardíaca crónica […]

RESILIENCE, a project to reduce the prevalence of heart failure in cancer survivors

Cancer patients are a vulnerable population prone to develop cardiovascular complications. Among other factors, some anticancer therapies can induce adverse cardiovascular effects. Every year, more than 3 million Europeans receive aCancer patients are a vulnerable population prone to develop cardiovascular complications. Among other factors, some anticancer therapies can induce adverse cardiovascular effects. Every year, more […]

Logotipo Resilience

Are you a patient participating in RESILIENCE? Here you will find useful information about the details of your participation, activities specifically designed for you. You will also be able to contact RESILIENCE researchers.

In accordance with the provisions of Regulation (EU) 2016/679 on the protection of personal data of natural persons (GDPR), the personal information you have provided will be incorporated into the data processing systems of the Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.) for the purpose of attending your registration application in the restricted area for patients participating in the RESILIENCE study. The legal basis for processing your personal data for this purpose is your explicit consent. Your personal data will not be disclosed to any recipients other than those to whom you authorise or when required by law to do so. You may exercise your rights of access, right to rectification, to object, to erasure, to restriction of processing, data portability and not to be subject to automated individual decision-making. To exercise these rights, as well as to obtain additional information about the processing of your personal data, you can consult the following link Terms and Conditions